CELU
Price
$2.23
Change
-$0.04 (-1.76%)
Updated
Oct 15, 11:12 AM (EDT)
Capitalization
60.59M
Intraday Buy/Sell Signals
NVCT
Price
$6.03
Change
-$0.16 (-2.58%)
Updated
Oct 14 closing price
Capitalization
153.76M
27 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

CELU vs NVCT

Header iconCELU vs NVCT Comparison
Open Charts CELU vs NVCTBanner chart's image
Celularity
Price$2.23
Change-$0.04 (-1.76%)
Volume$250
Capitalization60.59M
Nuvectis Pharma
Price$6.03
Change-$0.16 (-2.58%)
Volume$59.55K
Capitalization153.76M
CELU vs NVCT Comparison Chart in %
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELU vs. NVCT commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELU is a Hold and NVCT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (CELU: $2.27 vs. NVCT: $6.03)
Brand notoriety: CELU and NVCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELU: 977% vs. NVCT: 72%
Market capitalization -- CELU: $60.59M vs. NVCT: $153.76M
CELU [@Biotechnology] is valued at $60.59M. NVCT’s [@Biotechnology] market capitalization is $153.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELU’s FA Score shows that 0 FA rating(s) are green whileNVCT’s FA Score has 0 green FA rating(s).

  • CELU’s FA Score: 0 green, 5 red.
  • NVCT’s FA Score: 0 green, 5 red.
According to our system of comparison, NVCT is a better buy in the long-term than CELU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELU’s TA Score shows that 4 TA indicator(s) are bullish while NVCT’s TA Score has 3 bullish TA indicator(s).

  • CELU’s TA Score: 4 bullish, 4 bearish.
  • NVCT’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both CELU and NVCT are a good buy in the short-term.

Price Growth

CELU (@Biotechnology) experienced а +11.27% price change this week, while NVCT (@Biotechnology) price change was -1.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.76%. For the same industry, the average monthly price growth was +13.99%, and the average quarterly price growth was +268.92%.

Reported Earning Dates

NVCT is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+0.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVCT($154M) has a higher market cap than CELU($60.6M). NVCT YTD gains are higher at: 11.460 vs. CELU (9.135). NVCT has higher annual earnings (EBITDA): -22.97M vs. CELU (-58.29M). NVCT has more cash in the bank: 26.8M vs. CELU (863K). CELU has higher revenues than NVCT: CELU (44.6M) vs NVCT (0).
CELUNVCTCELU / NVCT
Capitalization60.6M154M39%
EBITDA-58.29M-22.97M254%
Gain YTD9.13511.46080%
P/E RatioN/AN/A-
Revenue44.6M0-
Total Cash863K26.8M3%
Total Debt70.2MN/A-
FUNDAMENTALS RATINGS
CELU: Fundamental Ratings
CELU
OUTLOOK RATING
1..100
80
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CELUNVCT
RSI
ODDS (%)
Bullish Trend 8 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 8 days ago
76%
Bearish Trend 8 days ago
87%
Momentum
ODDS (%)
Bearish Trend 8 days ago
80%
Bullish Trend 8 days ago
87%
MACD
ODDS (%)
Bullish Trend 8 days ago
88%
Bullish Trend 8 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 8 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
78%
Bearish Trend 8 days ago
90%
Advances
ODDS (%)
Bullish Trend 27 days ago
83%
Bullish Trend 8 days ago
87%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 22 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 8 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BBBK42.251.75
+4.32%
Baker Boyer Bancorp
ADLRF13.17N/A
N/A
ALARIS EQUITY PARTNERS INCOME TR
MNRIF0.29N/A
N/A
Minor International Public Co., Ltd.
WXXWY8.99-0.25
-2.71%
Wuxi Biologics (Cayman) Inc
SPCO0.81-0.04
-5.03%
The Stephan Co.

CELU and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELU has been loosely correlated with ACOG. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CELU jumps, then ACOG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
+11.27%
ACOG - CELU
48%
Loosely correlated
-0.92%
RIGL - CELU
39%
Loosely correlated
+2.05%
CYBN - CELU
26%
Poorly correlated
+4.96%
SPRO - CELU
26%
Poorly correlated
+3.06%
NVCT - CELU
25%
Poorly correlated
-2.58%
More

NVCT and

Correlation & Price change

A.I.dvisor tells us that NVCT and PDSB have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVCT and PDSB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCT
1D Price
Change %
NVCT100%
-2.58%
PDSB - NVCT
33%
Poorly correlated
-3.03%
ADMA - NVCT
29%
Poorly correlated
+2.75%
SGMT - NVCT
28%
Poorly correlated
-1.18%
AGIO - NVCT
27%
Poorly correlated
-1.66%
ZLAB - NVCT
27%
Poorly correlated
-5.86%
More